Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23709Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Liu, T. | en |
| dc.contributor.author | Korantzopoulos, P. | en |
| dc.contributor.author | Li, G. | en |
| dc.contributor.author | Li, J. | en |
| dc.date.accessioned | 2015-11-24T19:35:28Z | - |
| dc.date.available | 2015-11-24T19:35:28Z | - |
| dc.identifier.issn | 1874-1754 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23709 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Atrial Fibrillation/*drug therapy/metabolism/physiopathology | en |
| dc.subject | Diabetes Mellitus, Type 2/drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Hypoglycemic Agents/therapeutic use | en |
| dc.subject | Inflammation/physiopathology | en |
| dc.subject | Oxidative Stress/physiology | en |
| dc.subject | Peroxisome Proliferator-Activated Receptors/metabolism | en |
| dc.subject | Thiazolidinediones/*therapeutic use | en |
| dc.title | The potential role of thiazolidinediones in atrial fibrillation | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.ijcard.2007.05.051 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17655946 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0167527307011783/1-s2.0-S0167527307011783-main.pdf?_tid=d34f2fe3c78d13ef25e129333e34ae66&acdnat=1333964361_e83cce29bb2bce26e8667b4e618bd845 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | Thiazolidinediones (TZDs) represent insulin sensitizing drugs that are being increasingly used for the treatment of type 2 diabetes. These agents have also pleiotropic properties that possibly contribute to their favorable cardiovascular effects. In particular, TZDs have anti-inflammatory and anti-oxidant potential while they modulate cardiovascular remodeling. On the other hand, atrial electrical and structural remodeling constitutes the substrate for atrial fibrillation (AF) development and perpetuation. Of note, inflammation and oxidative stress have been recently implicated in the pathogenesis of AF while non-channel blocking drugs with pleiotropic properties, including anti-inflammatory and anti-oxidant, seem to favorably affect atrial remodeling. It is therefore reasonable to assume that TZDs may have a role in the management of AF. Despite some limited observations, no study to date has examined the effect of TZDs therapy on AF development. In addition, the role of these agents in atrial remodeling has not been clarified yet. | en |
| heal.journalName | Int J Cardiol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Liu-2008-The potential role o.pdf | 87.62 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
